

10 Years

VALUE REPORT | 20 26



ntc

Novelty. Technology. Care.

TEN YEARS AND BEYOND

*Looking back with pride,
moving forward with ambition*



Dear Partners and Clients,

2026 marks an important milestone for NTC as we celebrate our first ten years.

In a relatively short time, we have built a robust and dynamic organization. What began as an entrepreneurial initiative has developed into an international company, with 300 partners in over 100 countries, two commercial affiliates and continuously expanding operations.

Our positive path has been driven by a clear and consistent approach: focusing on areas where we can create meaningful value, strengthen our development capabilities and build long-term partnerships based on trust and reliability.

From the beginning, we adopted a model designed to keep us agile and focused. By leveraging a broad network of partners while maintaining full ownership of development, quality and product strategy, we have been able to grow rapidly, adapt to change and ensure consistency in everything we deliver.

While growing, we have built a company with a clear identity, where accountability matters: at NTC people are empowered to take action and collaboration is part of our daily culture. This is reflected in both how we work together, as well as in how we engage with our partners.

Looking ahead, we will continue along this path with clarity and discipline, strengthening our position in ophthalmology, expanding our role as a B2B partner in selected therapeutic areas and further developing our portfolio and pipeline.

Sustainability is also becoming increasingly integrated into our way of operating, guiding our focus on efficiency, responsibility and long-term value creation.

Our first decade was about building strong foundations. The next phase will focus on scaling up what we have built and accelerating future growth.

This Value Report reflects where we stand today and the direction we are committed to.

Thank you for your continued trust.

Sincerely,

Riccardo Carbucicchio
Chief Executive Officer




**We prioritize Novelty, Technology and we Care for our partners,
our customers, our patients and our people.**

The following information is intended for healthcare professionals only.

IDENTITY CARD at 10 YEARS


2026 sees an important milestone for NTC: our 10th anniversary
What started as an ambitious vision has become a global journey



OUR VISION WHAT WE AIM TO BE

Our goal is to become the go-to company and standard-setter in ophthalmology and a trusted B2B partner in gynecology, gastro-metabolism and on selected projects.

We aim to be a point of reference and excellence for patients seeking new treatments.



OUR MISSION – HOW TO REACH THE GOAL

Our mission is to develop and provide **high-quality** pharmaceutical products and medical devices that address real clinical needs and improve patients' quality of life.

Using an evidence-based approach and working closely with partners and healthcare professionals, we transform scientific knowledge into reliable therapeutic solutions across ophthalmology and other selected therapeutic areas.


SCIENCE
Evidence-based approach

DEVELOPMENT
High-quality drugs & medical devices

COLLABORATION
Partners & healthcare professionals


IMPACT
Improve patients' quality of life

Transforming scientific knowledge into reliable therapeutic solutions




NETWORK

300+ partners across **100+ countries**, ensuring worldwide access to innovative therapeutic solutions



EXCELLENCE

First Italian ophthalmology company to launch globally with proven clinical success
More than 20 products marketed in over 15 countries worldwide
65% of our MD portfolio received MDR approval



INNOVATION

R&D-driven approach with **€50M invested** by 2027 in innovative medicines



In just a decade, thanks to the trust of our partners and the dedication of our team, we have grown into a dynamic international company

CONSOLIDATE

NTC has consolidated its commercial and scientific position worldwide

A GLOBAL PLATFORM BUILT ON PARTNERSHIP

NTC WORLDWIDE

700+ deals across
100+ countries

40 launches of NTC
products in 2025

Partnering with NTC means benefiting from continuous support across the entire product lifecycle, from launch to long-term market execution.

LISTENING IS THE KEY

NTC's approach is rooted in listening to market needs and continuously enhancing its portfolio through:

- New clinical data and scientific evidence
- Publications and lifecycle management initiatives
- Continuous product optimization

A growing competitive advantage for partners over time

Partners benefit from:

- Structured medical marketing support
- Access to new commercial and scientific insights
- Cross-country knowledge sharing and experience exchange

Global Medical Marketing Meetings further strengthen this model by enabling partners to:

- Engage with top KOLs
- Share best practices across markets
- Gain insight into developments that support brand growth

A STRONG SCIENTIFIC NETWORK

KOLs & CLINICAL EXCELLENCE

NTC works with leading international experts and centres of excellence, enhancing its scientific credibility and development capabilities.

NTC supports its partners in product launches by engaging internationally recognized Key Opinion Leaders, fostering scientific exchange and reinforcing the value proposition of its therapies in the medical community.

AN EXAMPLE OF CLINICAL COLLABORATION

The ophthalmology centre in Lublin, led by Prof. Robert Rejdak, is one of Europe's most advanced clinical hubs and is now involved in a new NTC clinical study on cataract surgery.

From scientific exchange to clinical development

EXPANDING MARKETS & PORTFOLIO

Strategic acquisition: in 2025 NTC acquired an ophthalmology business (glaucoma)

This transaction is a key step in NTC's growth, with the following results for NTC:

- >80% in ophthalmology
- Strengthened position in Europe
- Opportunity to enter the US market
- Expanded portfolio and greater global reach

A CONSOLIDATED & FLEXIBLE SUPPLY CHAIN

NTC continues to strengthen its operational model:

- 45 qualified CDMOs/CMOs
- Flexible manufacturing approach
- Tech transfer capabilities
- >90% of manufacturing partners based in the EU

Reduced complexity and optimized footprint.

EXECUTION AS A COMPETITIVE ADVANTAGE

In today's pharmaceutical landscape, predictability is key.

Partners rely on:

- Process stability
- Strong quality systems
- Rapid deviation management
- High data integrity
- Tech transfer readiness / double CMO availability on strategic products

Execution capability is defined by:

- Speed of decision-making along the quality chain
- Ability to maintain standards under pressure

A partnership proves its value not in stable conditions, but in complex ones.

DELIVERING SUSTAINABLE VALUE

By integrating partnerships, scientific collaboration, and operational excellence, NTC continues to:

- Strengthen its global positioning
- Enhance its scientific credibility
- Support partners with consistent, high-quality execution

SIMPLIFY

NTC streamlined its processes, portfolio and operations to improve efficiency and sharpen its focus



SIMPLIFYING FOR PARTNERS

ENHANCING CUSTOMER EXPERIENCE THROUGH SIMPLICITY AND RELIABILITY

At NTC, simplifying for partners means orchestrating complexity through a highly coordinated model in which each function is interconnected and contributes to a smooth, efficient system.

FROM STRATEGY TO EXECUTION


Business Development & Licensing Managers

They identify the right opportunities, position the NTC portfolio to the right market needs, and build strong, trust-based partnerships acting as catalysts for innovation and collaboration.

Key Account Managers


KAMs are a central point of contact, ensuring customer proximity and a seamless experience. They drive growth by:

- Understanding partner needs
- Coordinating internal functions
- Enabling fast and effective problem-solving



A fully integrated support ecosystem works behind the scenes to simplify every interaction:

- **Medical & Marketing** teams support product launches and lifecycle management, leveraging global insights and KOL engagement
- **Regulatory Affairs** ensures efficient dossier submission and market access
- **Customer Service** guarantees responsiveness and reliability across logistics, contracts and operations
- **Professional Artwork** ensures compliance while integrating partner requirements



SIMPLIFYING THE ORGANIZATION

ENABLING AGILITY THROUGH SIMPLIFIED AND SHARED PROCESSES

NTC continuously improves internal processes to increase agility and responsiveness:

Digitalization

Streamlined tools and systems enhance operational efficiency and data accessibility. **Space NTC:** this new platform for shared document access is now live, providing access to the latest HR, Quality and Legal documents at any time and from any digital device.

Knowledge sharing

Cross-functional collaboration enables faster alignment and better decision-making. **Fidati:** NTC's continuously update repository enables all employees to access verified information independently, helping to streamline and optimize workflows.

Faster decision-making

Lean processes reduce complexity and improve execution speed, supported by a flat organizational structure that fosters proximity to leadership and rapid escalation when needed.

SIMPLIFYING FOR PATIENTS

IMPROVING THE PATIENT EXPERIENCE THROUGH ACCESSIBLE AND EASY-TO-USE THERAPIES

NTC focuses on simplifying the treatment experience through:

Preservative-free solutions

Improving tolerability and long-term eye health. *For instance, the acquired glaucoma portfolio contains many preservative-free formulations widely recognized for their quality, efficacy, safety and use in clinical practice.*

Proprietary products and technologies

Developing differentiated therapeutic solutions by combining scientific innovation with advanced delivery systems to enhance efficacy, safety and the overall patient experience. *Our flagship levofloxacin-dexamethasone combination is indicated for the prevention and treatment of inflammation and the prevention of infection following cataract surgery in adults for one week only.*

Ease of use

User-friendly formats designed to support treatment adherence and patient comfort.

We launched the Imperial product line for dry eye, offering our partners a modern portfolio of dry eye products built on a device with exceptional drop control for precise dosing, an elongated tip for more accurate instillation and an ergonomic bottle requiring minimal squeeze force.

Simplification is a key enabler of NTC's operational excellence, supporting scalability, focus and long-term value creation


DELIVER

10 Years

Every number reflects disciplined execution and our ability to deliver, for our partners worldwide

From global partnerships and regulatory achievements to product quality, intellectual property and sustainable growth, NTC continued to translate strategy into measurable value for patients, healthcare professionals and partners around the world

Executing with consistency. Delivering with impact



MEDICAL DEVICES & FOOD SUPPLEMENTS

By maintaining existing MDD certifications and progressing the transition to MDR, NTC ensures portfolio continuity, supports future customer growth and facilitates access to international markets through robust regulatory compliance.

MDR Approvals: 21
Ongoing: 13
To be submitted: 3

65% of our portfolio is already MDR-compliant, ensuring fast and compliant market access for partners.


DRUGS

Hundreds of regulatory submissions have been managed with the relevant authorities to ensure continued compliance with European and non-European standards.

For the recently acquired ophthalmology portfolio, regulatory procedures began in the first quarter of 2026 to transfer approximately 80 Marketing Authorizations across 20 countries, primarily in Europe, to NTC and to manage approximately 25 registration dossiers covering roughly 900 Marketing Authorizations.

REGISTRATIONS MD AND FS IN 2025

APPROVALS n°
51 registrations obtained



PATENTS

278 European Patents
56 National Patents
13 Priority Documents
10 Patent Cooperation Treaty
8 Eurasian patents



OPERATIONAL RELIABILITY

QUALITY ASSURANCE

From production release to post-market monitoring, NTC maintains rigorous quality standards, ensuring consistent supply and quality across all markets.

Batches of medical devices: **477**

Batches of pharmaceutical products: **398**

Batches of food supplements: **88**

Complaints per unit sold: 0.007% (reflecting a high level of product reliability and partner trust)

PROCUREMENT

NTC fully outsources production to a network of 45 contract development and manufacturing organizations (CDMOs and CMOs) selected for their expertise and capabilities. It maintains close, collaborative relationships with these partners, involving their laboratories from the early stages of product research and development. This flexible, scalable model allows NTC to respond rapidly to market needs while ensuring continuity of supply and consistently high manufacturing standards.



SUSTAINABLE VALUE CREATION

GREEN PRODUCTS

Sustainable innovation is becoming an increasingly important source of value in healthcare. In response, NTC is developing a portfolio that is increasingly aligned with evolving market and regulatory expectations. Its green products* are designed to combine patient benefits, environmental responsibility and the rational use of therapies, contributing to the company growth while advancing its long-term sustainability goals.

42% of turnover comes from green products

* Products that help combat antibiotic resistance, preservative-free multidose and single-dose products, and products whose secondary packaging uses FSC-certified paper.

A DECADE OF PEOPLE, GROWTH AND ENGAGEMENT

While NTC celebrates its 10th anniversary, its HR practices have evolved over the past decade to support business growth and foster a people-centred culture aligned with the company's long-term development

PEOPLE MANAGEMENT & ORGANIZATION

In 2025, HR further strengthened governance and scalability across Italy and Spain, combining operational excellence with an increasingly strategic people agenda:

- **Workforce planning** practices were enhanced to anticipate organizational needs and support decisions on recruitment, succession and internal development
- Greater role clarity and a more advanced job architecture reinforced transparency, consistency and **opportunities for career growth**
- Core HR governance and process consistency were strengthened across locations, ensuring **compliance and alignment throughout the organization**

PERFORMANCE & LEADERSHIP

Performance management continued to be a key pillar of NTC's people strategy, supporting both individual accountability and organizational effectiveness:

- A more structured **feedback culture** was reinforced, encouraging continuous dialogue between managers and employees beyond formal performance reviews and strengthening transparency
- **Internal mobility and job rotation** initiatives supported capability building, cross-functional collaboration and organizational flexibility
- High-performing employees (talents) were recognized and developed through concrete opportunities for **internal career progression** into managerial and executive roles

LEARNING & DEVELOPMENT

Learning initiatives combined with internal expertise, external partnerships and digital enablement to strengthen both transversal and technical capabilities:

Classroom, blended and digital learning solutions, supported by the **Genius** e-learning platform, ensured accessibility, scalability and continuity of learning

Development initiatives focused on transversal competencies and emerging topics, including technologies shaping the future, such as artificial intelligence

Internal training programs were designed and delivered by leveraging internal expertise, ensuring alignment with company culture and changing business needs

A continuous learning mindset was promoted across the organization, **encouraging self-development**, curiosity and knowledge sharing




EMPLOYEE EXPERIENCE

The employee experience was improved at key stages of the employee journey, with particular attention to scalable onboarding and engagement initiatives:

- Structured blended **onboarding and re-onboarding programs** were continuously improved to support integration during periods of growth and organizational evolution
- **Employees were actively involved** through training activities, team-building initiatives, committees and internal engagement programs
- **Collaboration between HQ and field teams** was further strengthened through the participation of head office staff in sales meetings and ongoing operational support

WELLBEING & ENGAGEMENT



Employee wellbeing remains a long-standing priority for NTC and a central element of its sustainable people strategy, supporting work-life balance and the overall quality of the employee experience:

- Dedicated initiatives such as the **"La Vaporosa"** welfare program continued to support employees in both their personal and professional lives: an ironing service free of charge for the NTC employees in the head office
- Flexible working practices were further consolidated, including **working from home** arrangements and early Friday closures
- **Sustainable mobility initiatives**, including the **ATM (public transportation company in Milan) partnership**, contributed to employee wellbeing and environmental responsibility

KEY PEOPLE METRICS (2025)

Key people metrics confirm the development of NTC's people strategy, reflecting a growing organization, continued investment in development and a positive trend in employee retention.

119
employees*
(+4.4%
vs **2024)**



*132 employees -
update July 2026

Turnover
(decreasing
trend):
10.5%



Average
learning hours/
employee:
34.5



~4,000 total learning hours
Genius platform:

100 items, multilingual (Italy/Spain),
63 employees trained (vs 38 in 2024),
>400 hours,
10.4% of training delivered digitally



LOOKING AHEAD

Building on 10 years of growth, NTC will continue to develop its people strategy to support sustainable development, organizational effectiveness and long-term value creation:

- **Strengthen listening and feedback mechanisms** to anticipate changing needs and drive continuous improvement
- **Expand development and learning initiatives**, with an increasing focus on future skills and leadership capabilities
- **Reinforce ESG social priorities** through responsible, long-term people practices, advancing inclusion, equity and wellbeing and working towards UNI/PdR 125:2022 certification

R&D: WHERE THE CIRCLE OPENS AND CLOSES

*Innovation starts by listening and ends by creating tangible value
Our R&D model connects scientific research, clinical evidence and real-world medical needs through a continuous cycle of collaboration with healthcare professionals, patients, caregivers and partners*

ONE HEALTH APPROACH: SCIENCE WITH A BROADER PURPOSE

Alongside the fight against antimicrobial resistance, NTC develops therapeutic solutions designed to support treatment adherence, optimize treatment management and promote the appropriate use of therapies in daily clinical practice.

We believe innovation should not only address therapeutic efficacy but also contribute to the more responsible use of healthcare resources and treatments.

"Today, antibiotics that were once highly effective in ophthalmology are increasingly having to contend with the problem of resistance. Ophthalmology must continue investing in clinical evidence supporting effective treatments and prophylactic strategies while contributing to the global fight against antimicrobial resistance."

Prof. **Francesco Bandello**, Director of the Ophthalmology Unit at the IRCCS San Raffaele Hospital in Milan.

FROM INSIGHT TO INNOVATION

NTC maintains an ongoing dialogue with the medical community to identify unmet needs, define product profiles and support clinical development, while increasingly integrating a personalized medicine approach designed to address the specific needs of different patient populations and clinical settings.

Innovation becomes meaningful when it addresses practical needs.

Key development areas include:

- First-in-class eye drop formulations (combining an NSAID with a quinolone antibiotic) designed to rationalize the use of antibiotics and support long-term ocular health (NTC014)
- Proprietary technologies developed to enhance treatment effectiveness, safety and ease of use in ophthalmology, gynecology and wound healing (TiAB)
- User-friendly therapeutic solutions created to simplify patient journeys and daily clinical practice (NTC015, now Kleerkol®)

R&D IN NUMBERS

~3,000

patients treated in NTC-sponsored interventional clinical studies

17

Scientific Advice procedures

90

publications across the portfolio

2

observational surveys conducted for NTC015, currently being published, and NTC011, already published

KLEERKOL®: SCIENCE-BASED PUBLICATIONS TO RESPOND TO AN UNMET MEDICAL NEED



Review article on unmet needs
JGH - Journal of Gastroenterology and Hepatology
(IF. 3.7)



Pharmacokinetic results
CTS - Clinical and Translational Science
(IF. 3.1)



Gas evidence
CTS - Clinical and Translational Science
(IF. 3.1)



Dose-finding Phase II study
EJCP - European Journal of Clinical Pharmacology
(IF. 2.4)



Set up of a new gas-measuring device
Current Therapeutics



Phase III data
Digestive and Liver Disease
(IF. 4)

"Improving the patient experience during bowel preparation is essential to increasing participation in colorectal cancer screening programs. Simpler, faster and more tolerable solutions can help engage patients earlier, improve adherence to colonoscopy pathways, and ultimately contribute to earlier diagnosis and better survival outcomes."

Prof. **Cristiano Spada**, Director of the Digestive Surgical Endoscopy Department at the Gemelli University Hospital in Rome.

SCIENCE CONTINUES AFTER APPROVAL

Innovation does not stop at Marketing Authorization approval.

NTC's in-house Pharmacovigilance unit is staffed by highly qualified professionals who help ensure the safety of its medicinal products throughout their lifecycle. The team continues to monitor product safety after authorization and once products are on the market, generating evidence that supports physicians and protects patients.

A recently published five-year study evaluating Leviosa®, NTC's fixed-dose eye drop treatment for use after cataract surgery, confirmed its excellent safety profile and reinforced the value of continuous post-marketing monitoring.

The analysis highlighted the importance of pharmacovigilance in supporting clinical practice and long-term patient safety.

*Innovation starts with listening
Value is created when science becomes a cure*


PIPELINE

CODE	TARGET THERAPEUTIC INDICATION	GALENIC FORMULATION	POST GALENIC FORMULATION / PHASE II	PHASE III	REG/LAUNCH
NTC011 Quinolone antibiotic + steroid	OTITIS EXTERNA				
NTC014 Quinolone antibiotic + NSAID	POST-CATARACT SURGERY / OCULAR INFECTIONS				
NTC015 Osmotic Laxative	PREPARATION FOR COLONOSCOPY				

...AND SEVERAL PATENT-PROTECTED ASSETS

NTC PORTFOLIO

Driven by ongoing therapeutic innovation, NTC has built a portfolio of 57 medicines, 60 medical devices and 11 nutraceuticals. Ten years of extraordinary results achieved in the blink of an eye



GLAUCOMA: IN TREATING IOP, YOU HAVE TWO OPTIONS



GASTRO-METABOLISM

- Bowel preparation: powder for oral solution
- Meteorism: different pharmaceutical forms
- Hemorrhoids: gel
- IBS: probiotics
- Mouth ulcers: gel, mouthwash and spray
- Liver protection: nutraceuticals

GYNECOLOGY

- Vaginal infection: gel, softgel caps and probiotic
- Vaginal atrophy: gel
- Vaginal discomfort: gel, foam, wipes
- Mucosal repair: gel
- Iron deficiency: nutraceuticals

SUPPORTIVE CARE

- Wound healing: cream and spray
- Atopic dermatitis: gel
- Diabetic foot: cream

LOCAL PRESENCE, GLOBAL VISION

NTC Italy and Spain: proximity as a competitive advantage

NTC's commercial units in Italy and Spain serve as local organizations and strategic listening hubs, connecting the company with healthcare professionals and transforming insights into meaningful innovation in ophthalmology.

By combining local proximity with a global vision, both units strengthen NTC's ability to identify unmet needs, support physicians and continuously refine therapeutic solutions.

NTC IN ITALY




WHERE SCIENTIFIC PARTNERSHIP DRIVES INNOVATION

"Italian Innovation: listening to ophthalmologists, understanding clinical needs and transforming insights into therapeutic solutions."

Andrea Croce, General Manager, NTC Italy

Italy is where NTC's growth journey began and remains a key market for understanding changing clinical needs.

NTC has built long-standing relationships with ophthalmologists, creating a model based on scientific dialogue and continuous exchange. This close collaboration allows the company to gather valuable feedback directly from daily clinical practice and transform it into new ideas, technologies and therapeutic solutions.



Key differentiators:

- **Strong relationships** with ophthalmologists and scientific communities
- **Continuous listening** to identify unmet clinical needs
- **Products tested** and refined through direct market feedback
- **Scientific collaboration** supporting innovation

The recent launch of **Baiama®**, NTC's aflibercept biosimilar for retinal diseases, exemplifies how these ongoing partnerships strengthen the company's position in Italy and expand access to affordable ophthalmic treatments.



NTC IN SPAIN

COMMITMENT AND PROXIMITY AT THE SERVICE OF OPHTHALMOLOGY

"NTC Spain prioritizes strengthening its presence in high-potential territories by delivering high-quality medical visits, emphasizing its commitment to ophthalmology."

Pedro Zorita, General Manager, NTC Spain



NTC Spain continued to strengthen its national presence through a consolidated organization designed to provide extensive coverage and personalized support to healthcare professionals.

Its growth model is built around one principle: staying close to physicians and understanding their needs.




Key pillars:

- **Commitment to ophthalmologists** in addressing therapeutic needs and supporting surgical practice through a comprehensive approach to care before, during and after surgery
- **A close-to-customer structure:** a consolidated commercial team providing extensive coverage and in-depth market knowledge
- **A young yet robust DNA:** a corporate culture built on strong values and innovative solutions
- **Active listening:** at NTC, we ensure ongoing dialogue with healthcare professionals to identify and address unmet medical needs

Feedback from ophthalmologists helps improve products and enhance usability. A recent example is the redesign of Puro packaging into a softer, more ergonomic format to improve dosing precision and treatment adherence, helping elderly patients manage their ocular health independently and with ease.

DRIVING TOMORROW'S TALENT

NTC in Italy and Spain focuses on the present while also investing in the future of the specialty. The company's commitment to ophthalmology in Italy and Spain extends to the next generation of professionals. Through dedicated meetings and initiatives involving young ophthalmologists, NTC supports their clinical development and fosters an environment in which experiences and perspectives can be shared, enriching the entire scientific community.



NTC GROUP IN A NUTSHELL


10 Years

Manufacturing

45 CDMOs/CMOs

68% of the procurement budget for products is allocated to Italian suppliers

Turnover by therapeutic areas



R&D

€ 50 million invested*

11 controlled clinical studies

17 Scientific Advice procedures

3,000 patients enrolled in clinical studies

90 publications covering our entire portfolio

*By 2027

Environment

42% of turnover comes from green products

***85 tons** of marine litter collected through NTC initiatives (*jan-Dec 2025)

Social

119 employees*

4 generation in NTC:

Baby Boomers **6%** Millennials **40%**
Gen X **49%** Gen Z **5%**

* 132 employees - update July 2026

Patents

278 European patents

56 National Patents

13 Priority Documents

10 Patent Cooperation Treaty

8 Eurasian Patents

365 Total Patents

Governance

73% of NTC suppliers have signed our Code of Conduct

B2B

300+ partners in

100+ markets

B2C

2 ophthalmology franchises in

Italy and **Spain**

Products

120+ products available

700+ SKUs marketed

4 in-licensing agreements

TRUST AND TRANSPARENCY

Trust exists when one party can confidently rely on another party to act with integrity. Trust flows from transparency, which is sustained through the observance of several best practices, chief among which is a commitment to clear, consistent and continuous communication.

ACCOUNTABILITY

Accountability means taking ownership of our actions, which is a prerequisite for achieving the desired results. It means identifying, owning and solving challenges by taking action. It also means making promises and keeping them.

SENSE OF URGENCY

We never lose sight of the need to keep changing and developing so that we can continue to respond swiftly to shifting circumstances. A sense of urgency is a mindset.



PASSION

Driven by energy that comes from within, we develop and provide products and services that our clients do not yet know they need. Our enthusiasm and passion enable us to maintain the highest standards.

PEOPLE

We recognize, appreciate and nurture the talent and contributions of all our people to ensure that everyone feels part of a great team.

Years



Printed with plant vegetal oil based ink



For more information visit
www.ntcpharma.com